ErbB receptors: from oncogenes to targeted cancer therapies.

ErbB receptors: from oncogenes to targeted cancer therapies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

ErbB receptors: from oncogenes to targeted cancer therapies. Abstract Text:

Hongtao Zhang,Alan Berezov,Qiang Wang,Geng Zhang,Jeffrey Drebin,Ramachandran Murali,Mark I Greene,

Understanding the genetic origin of cancer at the molecular level has facilitated the development of novel targeted therapies. Aberrant activation of the ErbB family of receptors is implicated in many human cancers and is already the target of several anticancer therapeutics. The use of mAbs specific for the extracellular domain of ErbB receptors was the first implementation of rational targeted therapy. The cytoplasmic tyrosine kinase domain is also a preferred target for small compounds that inhibit the kinase activity of these receptors. However, current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.

ErbB receptors: from oncogenes to targeted cancer therapies. Publishing Authors By Initials

H Zhang,A Berezov,Q Wang,G Zhang,J Drebin,R Murali,MI Greene,

For similar enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-tyrosine kinases: receptor protein-tyrosine kinases: receptor, epidermal growth factor research abstracts see: enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-tyrosine kinases: receptor protein-tyrosine kinases: receptor, epidermal growth factor research

PUBMED ID PMID:

MEDLINE DATE:

ErbB receptors: from oncogenes to targeted cancer therapies. Journal Published:

PUBLICATION TYPE: Review

Journal: The Journal of clinical investigation

VOLUME: 117

Page Numbers: 2051-8

Journal Abbreviation: J. Clin. Invest.

ISSN: 0021-9738

DAY: 3

MONTH: Aug

YEAR: 2007

ErbB receptors: from oncogenes to targeted cancer therapies. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7802877

ErbB receptors: from oncogenes to targeted cancer therapies. Keywords Mesh Terms:

KEYWORDS: Receptor, Epidermal Growth Factor

MESH TERMS: metabolism

Chemical & Substance for Abstract: ErbB receptors: from oncogenes to targeted cancer therapies. Information

Substance Name: HER1 protein, human

Registry Number: EC 2.7.10.1

Grant and Affiliation Information for ErbB receptors: from oncogenes to targeted cancer therapies.

AFFILIATION: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6082, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA089481

ACRONYM: CA

MEDLINETA: J Clin Invest

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

ErbB receptors: from oncogenes to targeted cancer therapies Related Publications

• A DNA-translocating Snf2 molecular motor: Saccharomyces cerevisiae Rdh54 displays processive translocation and extrudes DNA loops.
• A functional magnetic resonance imaging investigation of short-term source and item memory for negative pictures.
• A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
• APOBEC3G and HIV-1:Strike and Counterstrike.
• Angiotensin II is a critical mediator of prazosin-induced angiogenesis in skeletal muscle.
• Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression.
• Bridging cultural chasms between providers and HIV-positive Haitians in Palm Beach County, Florida.
• Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
• Dirty superconductivity in the electron-doped cuprate Pr(2-x)Ce(x)CuO(4-delta): tunneling study.
• Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
• ErbB receptors: from oncogenes to targeted cancer therapies.
• FOXP3 actively represses transcription by recruiting the HAT/HDAC complex.
• Factors associated with medication hassles experienced by family caregivers of older adults.
• Gender-specific design in total knee arthroplasty.
• High-field Hall resistivity and magnetoresistance of electron-doped Pr2-xCexCuO4-delta.
• In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions.
• Isolation of signal transduction complexes using biotin and crosslinking methodologies.
• Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.
• Molecular profiles of mitogen activated protein kinase signaling pathways in orofacial development.
• PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma.
• Partial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma.
• Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model.
• Rapid determination of double-bond positions in monoenoic fatty acids by periodate-permanganate oxidation.
• Regulation of HIV-1 latency by T-cell activation.
• Relative quantification of peptide phosphorylation in a complex mixture using 18O labeling.
• Role of endothelial cell apoptosis in regulation of skeletal muscle angiogenesis during high and low salt intake.
• Spectrum and dynamics of the BCS-BEC crossover from a few-body perspective.
• Structural plasticity in the oestrogen receptor ligand-binding domain.
• The personal health record: a key to improving health care for seniors.
• Who runs? A demographic profile of runaway youth in the United States.